Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L) Financial Performance & Income Statement Overview
Review Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L) Income Statement & Financial Overview
View the income breakdown for Laboratorios Farmaceuticos Rovi, S.A. 0ILL.L across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $154.89M | $434.41M | $235.28M | $178.16M |
| Cost of Revenue | $64.49M | $152.05M | $71.96M | $67.85M |
| Gross Profit | $90.40M | $282.36M | $163.31M | $110.31M |
| Gross Profit Ratio | $0.58 | $0.65 | $0.69 | $0.62 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $6.30M |
| SG&A Expenses | $35.09M | $60.17M | $33.22M | $32.57M |
| Operating Expenses | $67.38M | $159.29M | $73.19M | $73.13M |
| Total Costs & Expenses | $131.87M | $166.19M | $145.16M | $140.98M |
| Interest Income | $568000.00 | $233000.00 | $127000.00 | $97000.00 |
| Interest Expense | $629000.00 | $1.78M | $976000.00 | $328000.00 |
| Depreciation & Amortization | $7.28M | $7.43M | $7.14M | $6.82M |
| EBITDA | $30.76M | $40.20M | $97.47M | $44.28M |
| EBITDA Ratio | $0.20 | $0.09 | $0.41 | $0.25 |
| Operating Income | $23.02M | $123.07M | $90.12M | $37.18M |
| Operating Income Ratio | $0.15 | $0.28 | $0.38 | $0.21 |
| Other Income/Expenses (Net) | -$170000.00 | -$1.52M | -$765000.00 | -$48000.00 |
| Income Before Tax | $22.85M | $121.55M | $89.36M | $37.13M |
| Income Before Tax Ratio | $0.15 | $0.28 | $0.38 | $0.21 |
| Income Tax Expense | $4.77M | $29.01M | $20.21M | $7.75M |
| Net Income | $18.10M | $92.54M | $69.15M | $29.38M |
| Net Income Ratio | $0.12 | $0.21 | $0.29 | $0.16 |
| EPS | $0.35 | $1.81 | $1.30 | $0.55 |
| Diluted EPS | $0.35 | $1.81 | $1.30 | $0.55 |
| Weighted Avg Shares Outstanding | $51.15M | $51.12M | $53.38M | $53.38M |
| Weighted Avg Shares Outstanding (Diluted) | $51.15M | $51.12M | $53.38M | $53.38M |
The company's financials show resilient growth, with revenue advancing from $178.16M in Q2 2024 to $154.89M in Q1 2025. Gross profit remained healthy with margins at 58% in Q1 2025 compared to 62% in Q2 2024. Operating income hit $23.02M last quarter, sustaining a consistent 15% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $30.76M. Net income dropped to $18.10M, while earnings per share reached $0.35. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan